Dr. Mitul Mehta, Eyedaptic Chief Medical Officer, will showcase a promising new visual aid for those people with age-related macular degeneration (AMD) at the Ophthalmic Innovation Summit at the American Academy of Ophthalmologists Conference, taking place at the Marriot Marquis in Chicago October 25th at 10:00am CST.
AMD is a degenerative eye disease where an individual loses their essential central vision. It is the leading cause of vision loss amongst people age 60 and older, affecting more than 150 million worldwide. This summit unites over 1,000 industry leaders to collaborate on the development and commercialization of innovative drugs and devices to address unmet clinical needs.
Earlier this year, Dr. Mehta demonstrated how the use of Augmented Reality (AR) devices with embedded simulated natural vision software can improve the vision of those affected by AMD and other retinal conditions. In this presentation, Dr. Mehta presents clinical trial data along with early usability studies from extended in-home usage demonstrating how Eyedaptic’s visual aids can serve as a practical replacement for low vision devices by enhancing quality of life.
“I am very excited to share this clinical data with fellow Ophthalmologists, eager to learn more about what is on the horizon for those with low vision, especially AMD patients, searching for a viable solution,” said Dr. Mitul Mehta, Chief Medical Officer and Co-founder of Eyedaptic. Mitul is a board-certified ophthalmologist with fellowship training in medical and surgical diseases of the retina at UCI’s Gavin Herbert Eye Institute.
“We are very encouraged with the successful progress of the usability studies,” states Jay Cormier, Founder & CEO of Eyedaptic. “We are looking forward to this opportunity to present new data and objective proof of efficacy to those searching for a low vision solution.”
Eyedaptic is a software technology company addressing unmet needs in the ophthalmic field, focused on developing and marketing visually assistive Augmented Reality (AR) devices with embedded simulated natural vision software in open market hardware platforms. Eyedaptic devices are designed to offer low vision consumers a non-invasive, mobile visual aid to address retinal field of vision impairments.
Eyedaptic is a privately held company that develops macular degeneration visual aids and simulated natural vision software for those suffering from AMD (Age Related Macular Degeneration). Where other vision solutions only offer magnification and contrast and limit the field of vision, Eyedaptic allows the user to see the entire picture through a proprietary simulated natural vision software technology. For more information or to request an interview, contact: email@example.com.
The OIS conference unites over 1,000 industry, entrepreneurial and clinical leaders to collaborate on the development and commercialization of innovative drugs and devices to address unmet clinical needs.
For Media Inquiries: